Hormone-related diseases and prostate cancer: An English national record linkage study

被引:21
作者
Watts, Eleanor L. [1 ]
Goldacre, Raphael [2 ]
Key, Timothy J. [1 ]
Allen, Naomi E. [3 ,4 ]
Travis, Ruth C. [1 ]
Perez-Cornago, Aurora [1 ]
机构
[1] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England
[2] Univ Oxford, Nuffield Dept Populat Hlth, NIHR Oxford Biomed Res Ctr, Unit Hlth Care Epidemiol,Big Data Inst, Oxford, England
[3] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England
[4] Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit, Oxford, England
基金
英国医学研究理事会;
关键词
epidemiology; IGF-I; hormones; prostate cancer; record-linkage; testosterone; TESTOSTERONE-REPLACEMENT THERAPY; KLINEFELTER-SYNDROME; MEDICAL PROGRESS; IGF-I; MEN; RISK; PREVALENCE;
D O I
10.1002/ijc.32808
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Insulin-like growth factor-I (IGF-I) and testosterone may be related to prostate cancer risk. Acromegaly is associated with clinically high IGF-I concentrations. Klinefelter's syndrome, testicular hypofunction and hypopituitarism are associated with clinically low testosterone concentrations. We aimed to investigate whether diagnosis with these conditions was associated with subsequent prostate cancer diagnosis and mortality. We used linked English national Hospital Episode Statistics and mortality data from 1999 to 2017 to construct and follow-up cohorts of men aged >= 35 years diagnosed with (i) acromegaly (n = 2,495) and (ii) hypogonadal-associated diseases (n = 18,763): Klinefelter's syndrome (n = 1,992), testicular hypofunction (n = 8,086) and hypopituitarism (n = 10,331). We estimated adjusted hazard ratios (HRs) and confidence intervals (CIs) for prostate cancer diagnosis and death using Cox regression in comparison with an unexposed reference cohort of 4.3 million men, who were admitted to hospital for a range of minor surgeries and conditions (n observed cases = 130,000, n prostate cancer deaths = 30,000). For men diagnosed with acromegaly, HR for prostate cancer diagnosis was 1.33 (95% CI 1.09-1.63; p = 0.005; n observed cases = 96), HR for prostate cancer death was 1.44 (95% CI 0.92-2.26; p = 0.11; n deaths = 19). Diagnosis with Klinefelter's syndrome was associated with a lower prostate cancer risk (HR = 0.58, 95% CI 0.37-0.91; p = 0.02; n observed cases = 19) and hypopituitarism was associated with a reduction in prostate cancer death (HR = 0.53, 95% CI 0.35-0.79; p = 0.002; n deaths = 23). These results support the hypothesised roles of IGF-I and testosterone in prostate cancer development and/or progression. These findings are important because they provide insight into prostate cancer aetiology.
引用
收藏
页码:803 / 810
页数:8
相关论文
共 50 条
  • [41] Risk of self-harm in patients with eating disorders: English population-based national record-linkage study, 1999-2021
    Conway-Jones, R.
    James, A.
    Goldacre, M. J.
    Seminog, O. O.
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2024, 57 (01) : 162 - 172
  • [42] The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis
    Luca Cindolo
    Caterina Fanizza
    Marilena Romero
    Luisella Pirozzi
    Riccardo Autorino
    Francesco Berardinelli
    Luigi Schips
    World Journal of Urology, 2013, 31 : 665 - 671
  • [43] Differential risks of cancer types in people with Parkinson's disease: A national record-linkage study
    Ong, Eugene Liat Hui
    Goldacre, Raph
    Goldacre, Michael
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (14) : 2456 - 2462
  • [44] Work-related traffic crashes: A record linkage study
    Boufous, S
    Williamson, A
    ACCIDENT ANALYSIS AND PREVENTION, 2006, 38 (01) : 14 - 21
  • [45] The Impact of Homocysteine on the Risk of Hormone-Related Cancers: A Mendelian Randomization Study
    He, Qian
    Yang, Ze
    Sun, Yandi
    Qu, Zihao
    Jia, Xueyao
    Li, Jingjia
    Lin, Yindan
    Luo, Yan
    FRONTIERS IN NUTRITION, 2021, 8
  • [46] An integrated study of hormone-related sarcopenia for modeling and comparative transcriptome in rats
    Shu, Han
    Huang, Yubing
    Zhang, Wenqian
    Ling, Li
    Hua, Yuanyuan
    Xiong, Zhengai
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [47] A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs
    Bielo, Luca Boscolo
    Natangelo, Stefano
    Katrini, Jalissa
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (07) : 389 - 403
  • [48] Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs
    Li, Juan
    Ma, Zhiguo
    Jiang, Ren-wang
    Wu, Baojian
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (09) : 1085 - 1095
  • [49] Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer
    Wylaz, Mateusz
    Kaczmarska, Anna
    Pajor, Dawid
    Hryniewicki, Matthew
    Gil, Dorota
    Dulinska-Litewka, Joanna
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
  • [50] Hormone-related pathways and risk of breast cancer subtypes in African American women
    Stephen A. Haddad
    Kathryn L. Lunetta
    Edward A. Ruiz-Narváez
    Jeannette T. Bensen
    Chi-Chen Hong
    Lara E. Sucheston-Campbell
    Song Yao
    Elisa V. Bandera
    Lynn Rosenberg
    Christopher A. Haiman
    Melissa A. Troester
    Christine B. Ambrosone
    Julie R. Palmer
    Breast Cancer Research and Treatment, 2015, 154 : 145 - 154